Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolinapant with Paclitaxel +/- Bevacizumab in Recurrent Ovarian Cancer
NCT06393751Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Oct 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of tolinapant in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by National Cancer Institute. Primary endpoints: Incidence of dose-limiting toxicity at 28 days and Progression Free Survival up to 5 years. Planned start Oct 2025; status: withdrawn.
02
Drugs
tolinapant
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06393751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06393751.